Attached files
| file | filename |
|---|---|
| EX-31 - EXHIBIT 31 - OncoCyte Corp | ex31.htm |
| EX-23.1 - EXHIBIT 23.1 - OncoCyte Corp | ex23_1.htm |
| EX-10.29 - EXHIBIT 10.29 - OncoCyte Corp | ex10_29.htm |
| EX-10.26 - EXHIBIT 10.26 - OncoCyte Corp | ex10_26.htm |
| EX-4.5 - EXHIBIT 4.5 - OncoCyte Corp | ex4_5.htm |
| EX-4.4 - EXHIBIT 4.4 - OncoCyte Corp | ex4_4.htm |
| EX-4.3 - EXHIBIT 4.3 - OncoCyte Corp | ex4_3.htm |
| 10-K - ONCOCYTE CORPORATION 10-K 12-31-2016 - OncoCyte Corp | form10k.htm |
Exhibit 32
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of OncoCyte Corporation (the “Company”) for the year ended December 31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we William Annett, Chief Executive Officer, and Russell L. Skibsted, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: February 27, 2017
|
/s/ William Annett
|
||
|
William Annett
|
||
|
Chief Executive Officer
|
||
|
/s/ Russell L. Skibsted
|
||
|
Russell L. Skibsted
|
||
|
Chief Financial Officer
|